Samsung Biologics Achieves Strong Financial Performance in Q1 2026
Samsung Biologics, a renowned leader in contract development and manufacturing, recently unveiled its financial outcomes for the first quarter of 2026. The company reported a remarkable revenue of KRW 1,257 billion and an operating profit of KRW 581 billion, which underscores its solid performance and adaptability in a fluctuating market.
Each step of growth has been primarily facilitated by the optimal utilization of its manufacturing plants, which include Plants 1 through 4, and the consistent execution of ongoing projects that cater to growing client demands. Notably, John Rim, the President and CEO of Samsung Biologics, emphasized the company’s operational capabilities, stating, "In the first quarter, Samsung Biologics delivered stable growth, supported by consistent execution across our manufacturing network and continued demand from clients."
The company's financial performance indicates a robust year-on-year growth compared to the previous quarter. In Q1 2025, Samsung Biologics reported revenue of KRW 999.5 billion, marking an increase of approximately KRW 257.6 billion from the same quarter in 2026. Additionally, the operating profit showcased an increase from KRW 430.2 billion to KRW 580.8 billion, reflecting a strong year-on-year change of KRW 150.6 billion. The EBITDA also grew by KRW 160.7 billion to reach KRW 675.3 billion compared to Q1 2025.
Furthermore, Samsung Biologics reported a cumulative contract value exceeding USD 21.4 billion, indicating robust demand for its services from global clients. The company has also achieved a significant milestone by completing its first commercial-scale engineering run at its antibody-drug conjugate facility, showcasing its execution capabilities across various modalities.
As part of its business strategy for 2026, Samsung Biologics is on track to meet its forecasted goals, reinforced by continuous operations across multiple plants and the planned ramp-up of Plant 5. The acquisition of a Rockville manufacturing facility in Maryland, USA, for USD 353 million signifies the company's commitment to expanding its footprint in the U.S. market, enhancing client proximity, and bolstering supply chain resilience in this crucial area.
In keeping with its forward-looking approach, the company also recently entered into a strategic partnership with the Coalition for Epidemic Preparedness Innovations (CEPI), aimed at reinforcing global health emergency preparedness through agile manufacturing and rapid response capabilities. Collaborations with major pharmaceutical firms like Eli Lilly and Company further expand its innovative endeavors and commitment to developing a robust biotechnology ecosystem.
Moreover, Samsung Biologics has strengthened its service offerings with enhanced capabilities in contract development and operations (CDO), which includes master cell bank production and vector construction for client projects. The company's dedication to quality is evidenced by the successful attainment of over 440 regulatory approvals, demonstrating its consistent focus on compliance and global market reliability.
In line with sustainability goals, Samsung Biologics has achieved an EcoVadis Platinum rating recognizing its outstanding corporate sustainability practices. Additionally, the company has completely validated its Product Carbon Footprint system through third-party evaluation and published its Environment, Social, and Governance (ESG) report to promote greater transparency and stakeholder engagement. To affirm its efforts, the company was awarded the Sustainability Leadership Award at the CDMO Leadership Awards, highlighting its commitment to advancing sustainable practices across its operations.
Overall, Samsung Biologics continues to position itself as a leader in the biotechnology manufacturing sector, showcasing strong operational performance while exploring innovative avenues to support healthcare advancements globally.
Each step of growth has been primarily facilitated by the optimal utilization of its manufacturing plants, which include Plants 1 through 4, and the consistent execution of ongoing projects that cater to growing client demands. Notably, John Rim, the President and CEO of Samsung Biologics, emphasized the company’s operational capabilities, stating, "In the first quarter, Samsung Biologics delivered stable growth, supported by consistent execution across our manufacturing network and continued demand from clients."
The company's financial performance indicates a robust year-on-year growth compared to the previous quarter. In Q1 2025, Samsung Biologics reported revenue of KRW 999.5 billion, marking an increase of approximately KRW 257.6 billion from the same quarter in 2026. Additionally, the operating profit showcased an increase from KRW 430.2 billion to KRW 580.8 billion, reflecting a strong year-on-year change of KRW 150.6 billion. The EBITDA also grew by KRW 160.7 billion to reach KRW 675.3 billion compared to Q1 2025.
Furthermore, Samsung Biologics reported a cumulative contract value exceeding USD 21.4 billion, indicating robust demand for its services from global clients. The company has also achieved a significant milestone by completing its first commercial-scale engineering run at its antibody-drug conjugate facility, showcasing its execution capabilities across various modalities.
As part of its business strategy for 2026, Samsung Biologics is on track to meet its forecasted goals, reinforced by continuous operations across multiple plants and the planned ramp-up of Plant 5. The acquisition of a Rockville manufacturing facility in Maryland, USA, for USD 353 million signifies the company's commitment to expanding its footprint in the U.S. market, enhancing client proximity, and bolstering supply chain resilience in this crucial area.
In keeping with its forward-looking approach, the company also recently entered into a strategic partnership with the Coalition for Epidemic Preparedness Innovations (CEPI), aimed at reinforcing global health emergency preparedness through agile manufacturing and rapid response capabilities. Collaborations with major pharmaceutical firms like Eli Lilly and Company further expand its innovative endeavors and commitment to developing a robust biotechnology ecosystem.
Moreover, Samsung Biologics has strengthened its service offerings with enhanced capabilities in contract development and operations (CDO), which includes master cell bank production and vector construction for client projects. The company's dedication to quality is evidenced by the successful attainment of over 440 regulatory approvals, demonstrating its consistent focus on compliance and global market reliability.
In line with sustainability goals, Samsung Biologics has achieved an EcoVadis Platinum rating recognizing its outstanding corporate sustainability practices. Additionally, the company has completely validated its Product Carbon Footprint system through third-party evaluation and published its Environment, Social, and Governance (ESG) report to promote greater transparency and stakeholder engagement. To affirm its efforts, the company was awarded the Sustainability Leadership Award at the CDMO Leadership Awards, highlighting its commitment to advancing sustainable practices across its operations.
Overall, Samsung Biologics continues to position itself as a leader in the biotechnology manufacturing sector, showcasing strong operational performance while exploring innovative avenues to support healthcare advancements globally.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.